Browse > Article

Current Opinions on the Radioiodine Treatment of Graves' Hyperthyroidism  

Lee, Sang-Woo (Department of Nuclear Medicine, Kyungpook National University School of Medicine)
Lee, Jae-Tae (Department of Nuclear Medicine, Kyungpook National University School of Medicine)
Publication Information
The Korean Journal of Nuclear Medicine / v.37, no.6, 2003 , pp. 341-354 More about this Journal
Abstract
Radioactive iodine therapy using I-131 for hyperthyroidism has been used for more than 50 years, and generally considered safe and devoid of major side effects. Appropriate patient selection criteria and clinical judgement concerning patient preparation should be employed for its optimal use. It has not been possible to resolve the trade-off between efficient definite cure of hyperthyroidism and the high incidence of post-therapy hypothyroidism. The dose of the I-131 needed to maintain euthyroid state remains an area of uncertainity and debate. Early side effects are uncommon and readily managable. Other than the need for long-term monitoring and, in most cases, lifelong thyroid hormone treatment for late adverse consequences of this treatment remains only conjectural. We have reviewed general principles and recent advances in radioiodine treatment for Graves' hyperthyroidism, specially regarding to several controversies.
Keywords
radioiodine treatment; Graues' hyperthyroidism;
Citations & Related Records
연도 인용수 순위
  • Reference
1 조보연, 고창순. 한국에서 그레이브스병의 진단과 치 료 현황. -설문조사 분석 및 유럽, 미국, 일본과의 비 교. 대한내분비학회지 1992;7:216-27
2 Hall P, Boice JD Jr, Berg G, Bjelkengren G, Ericsson UB, Hallquist A, Lidberg M, Lundell G, Mattsson A, Tennvall J, et al. Leukaemia incidence after iodine-131 exposure. Lancet 1992;340:1-4   PUBMED
3 Lind P. Strategies of radioiodine therapy for Graves' disease. Eur J Nucl Med 2002;29:S453-7   DOI   ScienceOn
4 Wang CY, Chang TJ, Chang TC, Hsiao YL, Chen MH, Huang SH. Thyroidectomy or radioiodine? The value of ultrasonography and cytology in the assessment of nodular lesions in Graves' hyperthyroidism. Am Surg 2001;67:721-6   PUBMED
5 Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism-- prognostic factors for outcome. J Clin Endocrinol Metab 2001;86:3611-7   DOI   ScienceOn
6 Jarlov AE, Hegedus L, Kristensen LO, Nygaard B, Hansen JM. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clin Endocrinol 1995;43:325-9
7 Kok SW, Smit JW, de Craen AJ, Goslings BM, van Eck-Smit BL, Romijn JA: Clinical outcome after standardized versus dosimetric radioiodine treatment of hyperthyroidism: an equivalence study. Nucl Med Commun 2000;21:1071-8   DOI   ScienceOn
8 Moka D, Voth E, Schicha H. Effect of antithyroid medication on the effective half-life and uptake of 131-iodine following radioiodine therapy. Nuklearmedizin 1997;36:87-92   PUBMED
9 Moka D, Dietlein M, Schicha H. Radioiodine therapy and thyrostatic drugs and iodine. Eur J Nucl Med 2002;29:S486-91   DOI   ScienceOn
10 Bartalena L, Pinchera A, Marcocci C: Management of Graves' ophthalmopathy. reality and perspectives. Endocrine Reviews 2000;21:168-99   DOI   ScienceOn
11 DeGroot LJ. Radioiodine and the immune system. Thyroid 1997;7:259-64   DOI   PUBMED   ScienceOn
12 Hennemann G, Krenning EP, Sankaranarayanan K. Place of radioactive iodine in treatment of thyrotoxicosis. Lancet 1986;1:1369-72   PUBMED
13 Weiss M, Gorges R, Hirsch F, Bader J, Tatsch K, Hahn K. Immunogenic hyperthyroidism following iodine-131 therapy of non-immunogenic, autonomous thyroid nodules: results of a multicenter evaluation. Med Klin 1999;94:239-43   DOI
14 배진호, 정신영, 안병철, 이재태, 이규보. I-131 치료 에 의한 Graves병의 악화. 대한핵의학회지 2003;5: 68p
15 Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell'Unto E, Bartolomei MP, Nardi M, Martino E, Pinchera A. Cigarette smoking and treatment outcome in Graves opthalmopathy. Ann Intern Med 1998;129:632-5   DOI   PUBMED   ScienceOn
16 Bonnema SJ, Bartalena L, Toft AD, Hegedus L. Controversies in radioiodine therapy: relation to ophthalmopathy, the possible radioprotective effect of antithyroid drugs, and use in large goitres. Eur J Endocrinol 2002;147:1-11   DOI   ScienceOn
17 Dale J, Daykin J, Holder R, Sheppard MC, Franklyn JA. Weight gain following treatment of hyperthyroidism. Clin Endocrinol 2001;55:233-9   DOI   ScienceOn
18 Safa AM, Schumacher OP, Rodriguez-Antunez A. Long-term follow-up results in children and adolescents treated with radioactive iodine($^131$I) for hyperthyroidism. N Engl J Med 1975;292:167-71   DOI   PUBMED   ScienceOn
19 Becker DV, Sawin CT. Radioiodine and thyroid disease: the beginning. Semin Nucl Med 1996;26 :155-64   DOI   ScienceOn
20 Howarth D, Epstein M, Lan L, Tan P, Booker J. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study. Eur J Nucl Med 2001;28:1489-95   DOI   ScienceOn
21 Ron E, Doody MM, Becker DV. Brill AB, Curtis RE, Goldman MB, Benjamin SH, Hoffman DA, McConahey WM, Maxon HR, Preston-Martin S, Warshauer ME, Wong FL, Boice Jr JD. Cancer mortality following treatment for adult hyperthyroidism. JAMA 1998;280:347-55   DOI   PUBMED   ScienceOn
22 ${\sim}$Tallstedt L, Lundell G, Taube A. Graves' ophthalmopathy and tobacco smoking. Acta Endocrinol 1993;129:147-50
23 Pinchera A, Bartalena L, Marcocci C. Therapeutic controversies. Radioiodine may be bad for Graves' ophthalmopathy, but.. J Clin Endocrinol Metab 1995;80:342-5
24 Franklyn JA, Daykin J, Drolc Z, Farmer M, Sheppard MC. Long-term follow-up of treatment of thyrotoxicosis by three different methods. Clin Endocrinol 1991;34:71-6   DOI
25 Solomon B, Glinoer D, Lagasse R, Wartofsky L. Current trends in the management of Graves' disease. J Clin Endocrinol Metab 1990;70:1518-24   DOI   PUBMED
26 Bogazzi F, Bartalena L, Brogioni S, Scarello G, Burelli A, Campomori A, Manetti L, Rossi G, Pinchera A, Martino E. Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab 1999;84:499-503   DOI   ScienceOn
27 이광우, 손현식, 한제호, 유순집, 윤건호, 강무일, 홍 관수, 차봉연, 손호영, 강성구. 그레이브스 갑상선기 능항진증 환자의 방사성옥소 치료에 있어서 10 mCi 투여군과 일반적 계산용량 투여군의 3년간 추적결과. 대한내분비학회지 1992;7;358-63
28 Reinhardt MJ, Brink I, Joe AY, Von Mallek D, Ezziddin S, Palmedo H, Krause TM. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med 2002;29:1118-24   DOI   ScienceOn
29 Sabri O, Zimny M, Schulz G, Schreckenberger M, Reinartz P, Willmes K, Buell U. Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication. J Clin Endocrinol Metab 1999;84:1229-33   DOI   ScienceOn
30 Marcocci C, Bruno-Bossio G, Manetti L, Tanda ML, Miccoli P, Iacconi P, Bartolomei MP, Nardi M, Pinchera A, Bartalena L. The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study. Clin Endocrinol 1999;51:503-8   DOI   ScienceOn
31 Berg GE, Michanek AM, Holmberg EC, Fink M. Iodine-131 treatment of hyperthyroidism. significance of effective half-life measurements. J Nucl Med 1996;37:228-32   PUBMED
32 Gorman CA. Therapeutic controversies. Radioiodine therapy does not aggravate Graves' ophthalmopathy. J Clin Endocrinol Metab 1995;80:340-2   DOI   PUBMED
33 Nygaard B, Faber J, Veje A, Hegedus L, Hanssen JM. Relation between thyroid stimulating immunoglobulin and transient thyrotoxicosis in 4 patients treated with I-131 for non-toxic multinodular goiter. Eur J Endocrinol 1994;130;7
34 Kaplan MM, Meier DA, Dwaorkin HJ. Treatment of hyperthyroidism with radioactive iodine. Endocrionol Metab Clin North Am 1998;27:205-22   DOI   ScienceOn
35 Bal CS, Kumar A, Pandey RM. A randomized controlled trial to evaluate the adjuvant effect of lithium on radioiodine treatment of hyperthyroidism. Thyroid 2002;12:399-405   DOI   ScienceOn
36 Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992;326:1733-8   DOI   PUBMED   ScienceOn
37 Wesche MF, Tiel-van Buul MM, Smits NJ, Wiersinga WM. Ultrasonographic versus scintigraphic measurement of thyroid volume in patients referred for $^131$I therapy. Nucl Med Commun 1998;19:341-6   DOI   PUBMED   ScienceOn
38 Reynolds LR, Kotchen TA. Antithyroid drugs and radioactive iodine. Fifteen years' experience with Graves' disease. Arch Intern Med 1979;139:651-3   DOI   ScienceOn
39 Weetman AP, Harrison BJ. Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy? J Endocrinol Invest 1998;21:472-5
40 Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab 2003;88:978-83   DOI   ScienceOn
41 Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998;338:73-8   DOI   ScienceOn
42 Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab 1974;38:976-98   DOI   PUBMED
43 Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism. one-year follow-up of a prospective, randomized study. J Clin Endocrinol Metab 2001; 86:3488-93   DOI   ScienceOn
44 Hancock LD, Tuttle RM, LeMar H, Bauman J, Patience T. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease. Clin Endocrinol 1997;47:425-30   DOI   ScienceOn
45 Tepmongkol S: Enhancement of radioiodine uptake in hyperthyroidism with hydrochlorothiazide. a prospective randomised control study. Eur J Nucl Med 2002;29:1307-10   DOI   ScienceOn
46 Stoffer SS, Hamburger JI. Inadvertent 131I therapy for hyperthyroidism in the first trimester of pregnancy. J Nucl Med 1976;17:146-9   PUBMED
47 Alexander EK, Larsen PR. High dose 131I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2002;87: 1073-7   DOI   ScienceOn
48 Graham GD, Burman KD. Radioiodine treatment of Graves' disease. An assessment of its potential risks. Ann Intern Med 1986;105:900-5   DOI   PUBMED   ScienceOn
49 Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, Saaf M, Hamberger B. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine-A prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab 1996;81:2986-93
50 Bonnema SJ, Bartalena L, Toft AD, Hegedus L. Controversies in radioiodine therapy. relation to opthalmopathy, the possible redioprotective effect of antithyroid drugs, and use in large goitres. Eur J Endocrionol 2002;147:1-11   DOI   ScienceOn
51 Vestergaard P, Rejnmark L, Weeke J, Hoeck HC, Nielsen HK, Rungby J, Laurberg P, Mosekilde L. Smoking as a risk factor for Graves' disease, toxic nodular goiter, and autoimmune hypothyroidism. Thyroid 2002;12:69-75   DOI   ScienceOn
52 Hayek A, Chapman EM, Crawford JD. Long-term results of treatment of thyrotoxicosis in children and adolescents with radioactive iodine. N Engl J Med 1970;283:949-53   DOI   PUBMED   ScienceOn
53 Gittoes NJ, Franklyn JA. Hyperthyroidism. Current treatment guidelines. Drugs 1998;55:543-53   DOI   ScienceOn
54 Imseis RE, Vanmiddlesworth L, Massie JD, Bush AJ, Vanmiddlesworth NR. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. J Clin Endocrinol Metab 1998;83: 685-7   DOI   ScienceOn
55 Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern Med 1990;150:1098-101   DOI   ScienceOn
56 Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA. Age and gender predict the outcome of treatment for Graves ' hyperthyroidism. J Clin Endocrinol Metab 2000;85:1038-42   DOI   ScienceOn
57 Bae SK. Radioiodine therapy of thyroid disease. Korean J Nucl Med 2001;35:P11-8
58 Nordyke RA, Gilbert FI Jr. Optimal I-131 dose for eliminating hyperthyroidism in Graves' disease. J Nucl Med 1991;32;411-6
59 Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol 1994;130: 494-7
60 Tuttle RM, Patience T, Budd S. Treatment with propylthiouracil before radioactive iodine therapy is associated with higher treatment failure rate than therapy with radioactive iodine alone in Graves' disease. Thyroid 1995;5:243-7   DOI   ScienceOn
61 Kalinyak JE, McDougall IR. Editorial. How should the dose of iodine-131 be determined in the treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab, 2003;88:975-7
62 Rini JN, Vallabhajosula S, Zanzonico P, Hurley JR, Becker DV, Goldsmith SJ. Thyroid uptake of liquid versus capsule $^1$I tracers in hyperthyroid patients treated with liquid $^1$I. Thyroid 1999;9:347-52   DOI   ScienceOn
63 Franklyn JA. The management of hyperthyroidism. N Engl J Med 1994;330:1731-8   DOI   PUBMED   ScienceOn
64 Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, Izumi M. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1991;1:129-35   DOI   ScienceOn
65 Meier DA, Brill DR, Becker DV, Clarke S, Silberstein EB, Royal HD, Balon HR. Procedure guideline for therapy of thyroid disease with iodine-131. J Nucl Med 2002;43:856-61   PUBMED
66 Willemsen UF, Knesewitsch P, Kreisig T, Pickardt CR, Kirsch CM. Functional results of radioiodine therapy with a 300-Gy absorbed dose in Graves' disease. Eur J Nucl Med 199;20:1051-5